Characterization of the deficit syndrome in drug-naive schizophrenia patients: The Role of spontaneous movement disorders and neurological soft signs

Schizophrenia Bulletin

Volumn 40, Issue 1, 2014, Pages 214-224

  Peralta, Victor ^a   Moreno Izco, Lucía ^a   Sanchez Torres, Ana ^a   García De Jalón, Elena ^a   Campos, Maria S ^a   Cuesta, Manuel J ^a  

^a Universidad Pública de Navarra   (Spain)

Author keywords

basal ganglia; deficit schizophrenia; drug naive; neurological signs; outcome; symptom remission

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADOLESCENT; ADULT; AGED; AKATHISIA; ARTICLE; CATATONIA; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; DISEASE DURATION; DISORIENTATION; DYSKINESIA; FEMALE; FUNCTIONAL STATUS; HOSPITAL ADMISSION; HUMAN; MALE; MENTAL DISEASE; MENTAL PATIENT; MIDDLE AGED; MOTOR DYSFUNCTION; NEGATIVE SYNDROME; NEUROBIOLOGY; NEUROLOGIC DISEASE; NEUROLOGIC EXAMINATION; OUTCOME ASSESSMENT; PARKINSONISM; PRIORITY JOURNAL; PSYCHOSIS; RATING SCALE; SCHIZOPHRENIA; SPONTANEOUS MOVEMENT DISORDER; YOUNG ADULT;

BASAL GANGLIA; DEFICIT SCHIZOPHRENIA; DRUG-NAIVE; NEUROLOGICAL SIGNS; OUTCOME; SYMPTOM REMISSION;

ADOLESCENT; ADULT; AGED; COMORBIDITY; DEPRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MOVEMENT DISORDERS; NERVOUS SYSTEM DISEASES; PREVALENCE; PRODROMAL SYMPTOMS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; SYNDROME; YOUNG ADULT;

EID: 84892638912     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbs152     Document Type: Article

References (64)

1. Carpenter WT Jr, Stephens JH. An attempted integration of information relevant to schizophrenic subtypes. Schizophr Bull. 1979;5:490-506.
2. Carpenter WT Jr. Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry. 1988;145:578-583.
3. Buchanan RW, Kirkpatrick B, Heinrichs DW, Carpenter WT Jr. Clinical correlates of the deficit syndrome of schizophrenia. Am J Psychiatry. 1990;147:290-294.
4. Fenton WS, McGlashan TH. Antecedents, symptom progression, and long-term outcome of the deficit syndrome in schizophrenia. Am J Psychiatry. 1994;151:351-356.
5. Kirkpatrick B, Buchanan RW, Ross DE, Carpenter WT Jr. A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatry. 2001;58:165-171.
6. Galderisi S, Maj M, Mucci A, et al. Historical, psychopathological, neurological, and neuropsychological aspects of deficit schizophrenia: a multicenter study. Am J Psychiatry. 2002;159:983-990.
7. Galderisi S, Maj M. Deficit schizophrenia: an overview of clinical, biological and treatment aspects. Eur Psychiatry. 2009;24:493-500.
8. Whitty PF, Owoeye O, Waddington JL. Neurological signs and involuntary movements in schizophrenia: intrinsic to and informative on systems pathobiology. Schizophr Bull. 2009;35:415-424.
9. Chen EY, Lam LC, Chen RY, Nguyen DG. Negative symptoms, neurological signs and neuropsychological impairments in 204 Hong Kong Chinese patients with schizophrenia. Br J Psychiatry. 1996;168:227-233.
10. Sandyk R, Kay SR. The relationship of negative symptoms to parkinsonism. Int J Neurosci. 1990;55:1-59.
11. Brown KW, White T. The association among negative symptoms, movement disorders, and frontal lobe psychological deficits in schizophrenic patients. Biol Psychiatry. 1991;30:1182-1190.
12. McGlashan TH, Fenton WS. The positive-negative distinction in schizophrenia. Review of natural history validators. Arch Gen Psychiatry. 1992;49:63-72.
13. Telfer S, Shivashankar S, McCreadie RG, Kirkpatrick B. Tardive dyskinesia and deficit schizophrenia. Acta Psychiatr Scand. 2011;124:357-362.
14. Arango C, Kirkpatrick B, Buchanan RW. Neurological signs and the heterogeneity of schizophrenia. Am J Psychiatry. 2000;157:560-565.
15. Tiryaki A, Yazici MK, Anil AE, Kabak E, Karaaaolu E, G A. Reexamination of the characteristics of the deficit schizophrenia patients. Eur Arch Psychiatry Clin Neurosci. 2003;253:221-227.
16. Schooler N. Deficit symptoms in schizophrenia: negative symptoms versus neuroleptic-induced negative deficits. Acta Psychiatr Scand. 1994;380:21-26.
17. Ayd FJ. A survey of drug-induced extrapyramidal reactions. JAMA. 1961;175:1054-1060.
18. Caroff SN, Mann SC, Campbell EC, Sullivan KA. Movement disorders associated with atypical antipsychotic drugs. J Clin Psychiatry. 2002;63(suppl 4):12-19.
19. Gupta S, Andreasen NC, Arndt S, et al. Neurological soft signs in neuroleptic-naive and neuroleptic-treated schizophrenic patients and in normal comparison subjects. Am J Psychiatry. 1995;152:191-196.
20. Dazzan P, Murray RM. Neurological soft signs in firstepisode psychosis: a systematic review. Br J Psychiatry. 2002;181(suppl 43):50-57.
21. Fenton WS, Wyatt RJ, McGlashan TH. Risk factors for spontaneous dyskinesia in schizophrenia. Arch Gen Psychiatry. 1994;51:643-650.
22. Peralta V, Cuesta MJ. Neuromotor abnormalities in neuroleptic-naive psychotic patients: antecedents, clinical correlates, and prediction of treatment response. Compr Psychiatry. 2011;52:139-145.
23. Peralta V, Campos MS, de Jalon EG, Cuesta MJ. DSM-IV catatonia signs and criteria in first-episode, drugnaive, psychotic patients: psychometric validity and response to antipsychotic medication. Schizophr Res. 2010;118:168-175.
24. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). 4th ed. Washington, DC: American Psychiatric Association; 1994.
25. Andreasen NC, Flaum M, Arndt S. The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology. Arch Gen Psychiatry. 1992;49:615-623.
26. Peralta V, de Leon J, Cuesta MJ. Are there more than two syndromes in schizophrenia? A critique of the positive-negative dichotomy. Br J Psychiatry. 1992;161:335-343.
27. Hollingshead AB, Redlich FC. Social Class and Mental Illness: A Community Study. New York, NY: John Wiley & Sons; 1958.
28. Cannon M, Jones P, Gilvarry C, et al. Premorbid social functioning in schizophrenia and bipolar disorder: similarities and differences. Am J Psychiatry. 1997;154:1544-1550.
29. Perkins DO, Leserman J, Jarskog LF, et al. Characterizing and dating the onset of symptoms in psychotic illness: the Symptom Onset in Schizophrenia (SOS) inventory. Schizophr Res. 2000;44:1-10.
30. Kirkpatrick B, Buchanan RW, McKenney PD, Alphs LD, Carpenter WT Jr. The schedule for the deficit syndrome: an instrument for research in schizophrenia. Psychiatry Res. 1989;30:119-123.
31. Peralta V, Cuesta MJ. The deficit syndrome of the psychotic illness. A clinical and nosological study. Eur Arch Psychiatry Clin Neurosci. 2004;254:165-171.
32. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiat Scand. 1970;212:11-19.
33. Guy WA. Abnormal Involuntary Movement Scale (AIMS). In: ECDEU Assessment Manual for Psychopharmacology. Washington, DC: US Department of Health, Education, and Welfare; 1976:534-537.
34. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry. 1982;39:486-487.
35. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676.
36. Lund, CE, Mortimer, AM, Rogers, D, et al. Motor, volitional and behavioural disorders in schizophrenia. 1: assessment using the Modified Rogers Scale. Br J Psychiatry. 1991;158:323-327.
37. Buchanan RW, Heinrichs DW. The Neurological Evaluation Scale (NES): a structured instrument for the assessment of neurological signs in schizophrenia. Psychiatry Res. 1989;27:335-350.
38. Peralta V, de Jal? EG, Campos MS, Basterra V, Sanchez-Torres A, Cuesta MJ. Risk factors, premorbid functioning and episode correlates of neurological soft signs in drug-naive patients with schizophrenia-spectrum disorders. Psychol Med. 2010;22:1-11.
39. Endicott J, Spitzer RL, Fleiss JL, Cohen J. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry. 1976;33:766-771.
40. Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Arch Gen Psychiatry. 2005;162:441-449.
41. Amador XF, Kirkpatrick B, Buchanan RW, Carpenter WT, Marcinko L, Yale SA. Stability of the diagnosis of deficit syndrome in schizophrenia. Am J Psychiatry. 1999;156:637-639.
42. Kimhy D, Yale S, Goetz RR, McFarr LM, Malaspina D. The factorial structure of the schedule for the deficit syndrome in schizophrenia. Schizophr Bull. 2006;32:274-278.
43. Nakaya M, Ohmori K. A two-factor structure for the schedule for the deficit syndrome in schizophrenia. Psychiatry Res. 2008;158:256-259.
44. Kelley ME, Gilbertson M, Mouton A, van Kammen DP. Deterioration in premorbid functioning in schizophrenia: a developmental model of negative symptoms in drug-free patients. Am J Psychiatry. 1992;149:1543-1548.
45. Malla AK, Norman RM, Takhar J, et al. Can patients at risk for persistent negative symptoms be identified during their first episode of psychosis? J Nerv Ment Dis. 2004;192:455-463.
46. Strauss GP, Allen DN, Miski P, Buchanan RW, Kirkpatrick B, Carpenter WT Jr. Differential patterns of premorbid social and academic deterioration in deficit and nondeficit schizophrenia. Schizophr Res. 2012;135:134-138.
47. Yung AR, Phillips LJ, Yuen HP, McGorry PD. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophr Res. 2004;67:131-142.
48. Perkins DO, Gu H, Lieberman JA. Relationship between duration of untreated illness and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry. 2005;162:1785-1804.
49. Melle I, Larsen TK, Haahr U., et al. Prevention of negative symptom psychopathologies in first-episode schizophrenia. Arch Gen Psychiatry. 2008;65:634-640.
50. Buchanan RW, Breier A, Kirkpatrick B, Ball P, Carpenter WT Jr. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry. 1998;155:751-760.
51. Kirkpatrick B, Fisher B. Subdomains within negative symptoms of schizophrenia: commentary. Schizophr Bull. 2006;32:2006-2009.
52. Walker EF, Savoie T, Davis D. Neuromotor precursors of schizophrenia. Schizophr Bull. 1994;20:441-451.
53. Mittal VA, Neumann C, Saczawa M, Walker EF. Longitudinal progression of movement abnormalities in relation to psychotic symptoms in adolescents at high risk of schizophrenia. Arch Gen Psychiatry. 2008;65:165-171.
54. Obiols JE, Serrano F, Caparr? B, Subir? S, Barrantes N. Neurological soft signs in adolescents with poor performance on the continous performance test: markers of liability for schizophrenia spectrum disorders? Psychiatry Res. 1999;86:217-228.
55. Prasad KM, Sanders R, Sweeney J, et al. Neurological abnormalities among offspring of persons with schizophrenia: relation to premorbid psychopathology. Schizophr Res. 2009;108:163-169.
56. Peralta V, Cuesta MJ. The effect of antipsychotic medication on neuromotor abnormalities in neuroleptic-naive nonaffective psychotic patients: a naturalistic study with haloperidol, risperidone, or olanzapine. Prim Care Companion J Clin Psychiatry. 2010;12. pii: PCC.09m00799.
57. Obeso JA, Rodriguez-Oroz MC, Rodriguez M, Arbizu J, Gim?ez-Amaya JM. The basal ganglia and disorders of movement. News Physiol Sci. 2002;17:51-55.
58. Caroff SN, Mann SC, Francis A, Friccione GL. Catatonia: From Psychopathology to Neurobiology. Washington, DC: American Psychiatric Publishing Inc.; 2004.
59. Scheuerecker J, Ufer S, K?ernick M, et al. Cerebral network deficits in post-acute catatonic schizophrenic patients measured by fMRI. J Psychiatr Res. 2009;43:607-614.
60. Dazzan P, Morgan KD, Orr KG, et al. The structural brain correlates of neurological soft signs in AESOP first-episode psychoses study. Brain. 2004;127:143-153.
61. Thomann PA, W?tenberg T, Santos VD, Bachmann S, Essig M, Schr?er J. Neurological soft signs and brain morphology in first-episode schizophrenia. Psychol Med. 2009;39:371-379.
62. Janssen J, Diaz-Caneja A, Reig S, et al. Brain morphology and neurological soft signs in adolescents with first-episode psychosis. Br J Psychiatry. 2009;195:227-233.
63. Ehrlich S, Yendiki A, Greve DN, et al. Striatal function in relation to negative symptoms in schizophrenia. Psychol Med. 2012;42:267-282.
64. Navari S, Dazzan P. Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings. Psychol Med. 2009;39:1763-1777.